About Rubius Therapeutics
Rubius Therapeutics is a company based in Cambridge (United States) founded in 2015. Rubius Therapeutics has raised $245 million across 4 funding rounds from investors including Flagship Pioneering and SLR Investment Corp. The company has 256 employees as of December 31, 2022. Rubius Therapeutics operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter Cambridge, United States
- Employees 256 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rubius Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$245 M (USD)
in 4 rounds
-
Latest Funding Round
$25 M (USD), Debt – Conventional
Dec 21, 2018
-
Investors
Flagship Pioneering
& 1 more
-
Employee Count
256
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Rubius Therapeutics
Unlock access to complete
Funding Insights of Rubius Therapeutics
Rubius Therapeutics has successfully raised a total of $245M across 4 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $25 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rubius Therapeutics
Rubius Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Flagship Pioneering and SLR Investment Corp.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Debt and equity investments are offered by the firm.
|
Locked | Locked | Locked | |
|
Life sciences-focused venture capital firm
|
Locked | Locked | Locked |
Investor details for Rubius Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rubius Therapeutics
Investment portfolio details for Rubius Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rubius Therapeutics
Detailed financials for Rubius Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rubius Therapeutics Comparisons
Peer comparison for Rubius Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rubius Therapeutics
Rubius Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Detailed competitors of Rubius Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rubius Therapeutics
Complete news archive for Rubius Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rubius Therapeutics
Rubius Therapeutics was founded in 2015.
Rubius Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Rubius Therapeutics is a funded company, having raised a total of $245M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Rubius Therapeutics is 256.
Rubius Therapeutics was founded in 2015 in Cambridge, United States, within the biotechnology sector. The companys operations focus on the Erythrocyte Design platform, where hematopoietic stem cells are genetically altered to produce functionalized red blood cells expressing biotherapeutic proteins. These therapeutics are developed for applications in metabolic deficiencies, autoimmune disorders, and cancer, with over 50 prototypes validated in preclinical models.
Rubius Therapeutics's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
Rubius Therapeutics has 2 investors. Key investors include Flagship Pioneering, and SLR Investment Corp.